ProCE Banner Activity

Hot Off the Press: New Data on the Use of Acalabrutinib to Manage Patients With Severe COVID-19

Clinical Thought
What conclusions can we draw from these preliminary data for the use of BTK inhibitors to treat the hyperinflammatory immune response in patients with severe COVID-19?

Released: June 16, 2020

Expiration: June 15, 2021

No longer available for credit.

Share

Faculty

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, Genentech, Pharmacyclics, and TG Therapeutics.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, Genentech, Pharmacyclics, and TG Therapeutics.